Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Alan F List, MD
H. Lee Moffitt Cancer Center and Research Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
32 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- St. Johannes Hospital
Duisburg, Germany
- Arizona Cancer Center
Scottsdale, Arizona, United States
- Mayo Clinic
Scottsdale, Arizona, United States
- Arizona Cancer Center
Tucson, Arizona, United States
- Desert Hematology & Oncology Medical Group
Rancho Mirage, California, United States
- Stanford University Medical Center
Stanford, California, United States
- Mayo Clinic
Jacksonville, Florida, United States
- Cancer & Blood Disease Center
Lecanto, Florida, United States
- University of Miami Sylvester Comp Cancer Center
Miami, Florida, United States
- H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
- Northwest Georgia Oncology - Wellstar Cancer Research
Marietta, Georgia, United States
- Rush-Presbyterian- St. Luke'S Medical Center
Chicago, Illinois, United States
- University of Chicago Medical Center
Chicago, Illinois, United States
- Midwest Cancer Research Group
Skokie, Illinois, United States
- Johns Hopkins Oncology Center
Baltimore, Maryland, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Wayne State University School of Medicine
Detroit, Michigan, United States
- Mayo Clinic
Rochester, Minnesota, United States
- University of Nebraska Medical Center
Omaha, Nebraska, United States
- Roswell Park Cancer Institute
Buffalo, New York, United States
- Memorial Sloan-Kettering Cancer Center
New York, New York, United States
- Mt. Sinai Medical Center
New York, New York, United States
- New York Hospital-Cornell
New York, New York, United States
- University of Rochester- James P. Wilmot Cancer Center
Rochester, New York, United States
- Wake Forest University School of Medicine
Winston-Salem, North Carolina, United States
- the Cleveland Clinic Foundation
Cleveland, Ohio, United States
- Kaiser Permanente Northwest Region
Portland, Oregon, United States
- Oregon Health & Science University
Portland, Oregon, United States
- Western Pennsylvania Cancer Institute
Pittsburgh, Pennsylvania, United States
- Md Anderson Cancer Center
Houston, Texas, United States
- Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
- Swedish Cancer Institute
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Jun 2003
- Primary completion
- 1 Aug 2008
- Completion
- 1 Aug 2008
- Last update posted
- 19 Nov 2019
- Registered enrollment
- 148
- Registry id
- NCT00065156
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.